| A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). | |
| | |
MedLine Citation:
|
PMID: 15217926 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: High-dose intermittent cytarabine is an effective postremission treatment for patients with acute myeloid leukemia (AML). This regimen is a safe approach in patients < 60 years but produced severe neurotoxicity in the elderly. EXPERIMENTAL DESIGN: We have established a dose-reduced age-adapted consolidation using intermediate dose (IDAC; 2 x 1 g/m(2) i.v., days 1, 3, and 5) for AML patients >/= 60 years. Forty-seven de novo AML patients in complete remission (CR; median age, 70 years) were scheduled to receive four consolidation cycles of IDAC. RESULTS: In 25 of 47 patients (53%), all four cycles were administered: 9 (19%) received three cycles; 7 (15%) received two cycles; and 6 patients (12%) one cycle. Treatment was well tolerated without neurotoxicity. The median number of days with severe neutropenia (absolute neutrophil count < 500/microl) was 9. Neutropenic fever occurred in 22 of 47 patients (49%) during the first cycle, in 24 of 41 (60%) during the second, in 15 of 34 (44%) during the third, and in 18 of 25 (72%) during the fourth cycle. Only 1 patient died during consolidation (cardiac failure). The median overall survival, disease-free survival, and continuous CR were 10.6, 15.5, and 15.9 months, respectively. The probability of overall survival, disease-free survival, and continuous CR at 5 years were 18, 22, and 30%, respectively. CONCLUSIONS: IDAC is a safe and effective postremission therapy for elderly patients with AML. |
| | |
Authors:
|
Wolfgang R Sperr; Maria Piribauer; Friedrich Wimazal; Christa Fonatsch; Renate Thalhammer-Scherrer; Ilse Schwarzinger; Klaus Geissler; Paul Knöbl; Ulrich Jäger; Klaus Lechner; Peter Valent |
Related Documents
:
|
22138456 - Implementation of high-dose-rate brachytherapy and androgen deprivation in patients wit... 10089896 - Prognostic implications of cytogenetic aberrations in diffuse large b-cell lymphomas. 20956016 - Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk... 18072636 - Management of acute myeloid leukaemia--5 years experience at armed forces bone marrow t... 18347176 - Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell car... 20691886 - Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penil... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: 10 ISSN: 1078-0432 ISO Abbreviation: Clin. Cancer Res. Publication Date: 2004 Jun |
Date Detail:
|
Created Date: 2004-06-25 Completed Date: 2005-01-03 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 3965-71 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Institute of Medical Biology, and Institute of Medical and Laboratory Medicine, Medical University of Vienna, Vienna, Austria. wolfgang.r.sperr@univie.ac.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Antimetabolites, Antineoplastic / administration & dosage* Antineoplastic Agents, Phytogenic / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Cytarabine / administration & dosage* Daunorubicin / administration & dosage Disease-Free Survival Etoposide / administration & dosage Female Humans Karyotyping Leukemia, Myeloid, Acute / drug therapy*, genetics Male Middle Aged Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents, Phytogenic; 147-94-4/Cytarabine; 20830-81-3/Daunorubicin; 33419-42-0/Etoposide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Detection of prostate cancer and predicting progression: current and future diagnostic markers.
Next Document: Promoter hypermethylation profile of kidney cancer.